Assessment of Dose Response of LY333334 in Japanese Postmenopausal Women With Osteoporosis

Eli Lilly and Company6 个研究点分布在 1 个国家目标入组 160 人开始时间: 2005年2月最近更新: 2007年11月6日

适应症

试验速览

阶段: 2 期
状态: 已完成
发起方: Eli Lilly and Company
入组人数: 160
试验地点: 6
主要终点: To assess the dose response of LY333334 with the percent change from baseline in lumbar spine mineral density at endpoint

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The purpose of this study is to assess the Efficacy and Safety of Teriparatide in Japanese Postmenopausal Women with Osteoporosis.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment
盲法: Double

入排标准

年龄范围: 55 Years 至 —（Adult, Older Adult）
性别: Female
接受健康志愿者: 否

入选标准

•Japanese women with primary osteoporosis
•Postmenopausal women aged at least 55 years
•Patients with a high risk for fracture

排除标准

•History of metabolic bone disorders other than osteoporosis
•History of any secondary causes of osteoporosis
•History of malignant neoplasm within the last 5 years except for superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitively treated
•Severe or chronically disabling conditions other than osteoporosis

结局指标

主要结局

To assess the dose response of LY333334 with the percent change from baseline in lumbar spine mineral density at endpoint

次要结局

To evaluate the safety of LY333334

研究者

发起方

Eli Lilly and Company

申办方类型

Industry

研究点 (6)

Loading locations...

相似试验

已完成

1 期

A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 DiabetesType 2 Diabetes Mellitus

NCT03322631Eli Lilly and Company48

已完成

不适用

Assessment of Response to Thienopyridine in Japanese Population (ART-JP)coronary artery disease (CAD)

JPRN-UMIN000006336Keio University, School of Medicine, Research Park 5S9300

已完成

1 期

A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)Diabetes Mellitus, Type 2

NCT04823208Eli Lilly and Company64

已完成

1 期

A Study of LY3039478 in Japanese Participants With Advanced Solid TumorsAdvanced Solid Tumor

NCT02836600Eli Lilly and Company11

已完成

4 期

COMACHIHER2- positive inoperable or recurrent breast cancer

JPRN-jRCT1080222272Chugai Pharmaceutical Co., Ltd.132